Water-based cannabinoid and opioid compositions
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.
1. A tablet or capsule consisting essentially of a cannabis extract consisting essentially of at least one phyto-cannabinoid bound to a protein, wherein the protein is selected from the group consisting of: albumin, α globulin, β globulin, and γ globulin.
2. The tablet or capsule according to claim 1 , wherein the protein is albumin.
3. The tablet or capsule according to claim 1 , wherein the albumin is selected from the group consisting of recombinant albumin, human serum albumin, bovine serum albumin and egg albumin.
4. The tablet or capsule according to claim 1 , wherein the phyto-cannabinoid is selected from the group consisting of Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, tetrahydrocannabinoic acid, cannabidiol, cannabidiolic acid, cannabinol, cannabigerol, tetrahydrocannabivarin, cannabigerolic acid, and cannabichromene.
5. The tablet or capsule according to claim 4 , wherein the phyto-cannabinoid is cannabidiol.
6. The tablet or capsule according to claim 1 , wherein the phyto-cannabinoid is bound to one or more hydrophobic regions of the protein.
7. The tablet or capsule according to claim 1 , wherein the amount of phyto-cannabinoid in the tablet or capsule is between 1 mg and 1 g.
8. The tablet or capsule according to claim 1 , wherein the amount of protein-bound phyto-cannabinoid is between 0.1% and 95% of the tablet or capsule.
9. The tablet or capsule according to claim 1 , wherein the amount of protein-bound phyto-cannabinoid is between 1% and 70% of the tablet or capsule.